This case was reported by a consumer via sales rep and described the occurrence of leukopenia in a adult female patient who received SHINGRIX for prophylaxis. The patient's past medical history included sinus infection (History of Sinus infection) and sinus disorder (History of Sinus problems). Concomitant products included azathioprine (Imuran). On an unknown date, the patient started Nucala 300 mg at an unknown frequency. On an unknown date, an unknown time after starting Nucala, the patient experienced liver enzyme abnormal, white blood cell count abnormal, sinus infection, nausea and influenza-like symptoms. The action taken with Nucala was unknown. On an unknown date, the outcome of the liver enzyme abnormal, white blood cell count abnormal, sinus infection, nausea and influenza-like symptoms were unknown. It was unknown if the reporter considered the liver enzyme abnormal, white blood cell count abnormal, sinus infection, nausea and influenza-like symptoms to be related to Nucala. Additional details: Caller reported receiving her 1st dose of Nucala for Eosinophilic granulomatosis with polyangiitis and 2 weeks after, she received abnormal liver enzyme (Liver enzyme abnormal) and white blood cell count results (White blood cell count abnormal). The caller also mentioned nausea (Nausea), flu-like symptoms (Influenza-like symptoms), and that she was currently being treated for a sinus infection (Sinus infection). She did also state that she noticed that she was using her inhaler less. She has a history of sinus problems, but was not sure if it was now related to the new medication. No additional details provided. Follow up information was received from physician on 15th October 2018: The patient recently got SHINGRIX vaccine. In October 2018, the patient received Nucala subcutaneously for eosinophilic granulomatosis with polyangiitis (EGPA) 14 days before the date of reporting. MD called to ask if they were aware of any information that linked Nucala with increased liver function tests (LFTs) and leukopenia. The patient developed these lab abnormalities like leukopenia (serious criteria GSK medically significant), liver enzyme abnormal, white blood cell count abnormal, 2 weeks after receiving her 1st dose of Nucala for EGPA. MD seemed to think the adverse reaction was probably not related to Nucala, but wanted to check back. On an unknown date, less than a year after receiving SHINGRIX the patient experienced leukopenia (serious criteria GSK medically significant), liver enzyme abnormal, white blood cell count abnormal, sinus infection, nausea and influenza-like symptoms. On an unknown date, the patient started Imuran, Nystatin, Valacyclovir, Omeprazole, Tramadol, Xopenex, Prednisone and Ativan at an unknown dose and frequency. In October 2018, less than a year after receiving Shingrix, 14 days after starting Nucala and unknown after starting Imuran, nystatin, Valacyclovir and omeprazole, the patient experienced leukopenia (serious criteria GSK medically significant), liver enzyme abnormal, white blood cell count abnormal, sinus infection, nausea, influenza-like symptoms and liver function test increased. The action taken with Nucala was unknown. It was unknown if the reporter considered the leukopenia, liver enzyme abnormal, white blood cell count abnormal, sinus infection, nausea, influenza-like symptoms and liver function test increased to be related to Shingrix, Nucala, Imuran, nystatin, Valacyclovir and omeprazole. It was unknown if the reporter considered the leukopenia, liver enzyme abnormal, white blood cell count abnormal, sinus infection, nausea, influenza-like symptoms and liver function test increased to be related to Tramadol, Xopenex, Prednisone and Ativan as well.